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↑What is “already known” in this topic: 
There are a few studies that have assessed the oriented 
conjugation methods (Covalent binding via carbohydrate 
moieties on the FC region of antibody). The conjugation of 
anti-hCG antibody to paramagnetic nanoparticles is one of 
them which was tested successfully.   
 
→What this article adds: 
In this study the oriented conjugation method was done 
through carbohydrate moieties of the FC domains for anti-
PSCA antibody and dextran-superparamagnetic iron oxide 
nanoparticles for the first time in the world. In comparison with 
non-oriented conjugation, this method efficiently enhances the 
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Abstract 
    Background: The main property of a successful conjugation of antibodies to nanoparticles is keeping the potency of antibody for 
binding the antigen, and an oriented conjugation can do that. Under such ground, this study was carried out to explore the efficiency of 
two conjugation methods in binding iron nanoparticles to an antibody produced against PSCA (prostate stem cell antigen) using in 
vitro labeling of PC3 cells. 
   Methods: In this experimental study, we conjugated dextran-superparamagnetic iron oxide nanoparticles (dexSPIONs) to anti-PSCA 
antibody by two different methods, including targeting carbohydrate moieties in FC domain and the free amine group of amino acid 
side chains. Ultimately, Iron staining was done by anti-PSCA antibody-dexSPIONs in PC3 cells to detect antibody binding to the cells. 
   Results: A strong blue dye was induced by iron staining in conjugated dexSPIONs on the membrane of PC3 cells by the former 
method than the second one. Moreover, cells treated with 20 nm diameters of dexSPIONs showed higher resolution of blue color than 
those treated with 100 nm nanoparticles. 
   Conclusion: This oriented conjugation method promoted the efficiency of targeting tumor antigens, and the presence of iron 
particles might enhance MRI image intensity in vivo by targeting PSCA-overexpressing cells in future studies.  
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Cancer theranostics has been considerably improved 
with the advent and rapid progress of nanotechnology (1). 
Developing nanoscience-related strategies have provided 
more efficient and noninvasive approaches without serious-
ly damaging the healthy tissue in comparison with tradi-
tional cancer treatment methods such as chemotherapy (1). 
Among numerous nanomaterials studied in the cancer 
research field, superparamagnetic iron oxide nanoparticles 
(SPIONs) have been considered one of the most attractive 
candidates. In magnetic reso nance imaging (MRI), the 
SPIONs can be applied as a contrasting agent for diagno-
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ture (2, 3). These nanoparticles have interestingly low 
toxicity and are biodegradable. Furthermore, the small 
size of SPIONs facilitates the endocytosis and penetration 
into tissues and enhances drug-loading, which all make 
them the ideal candidate for molecular targeting (1, 4-6).  
In spite of the potential characteristics of SPIONs, using 
the unconjugated nanoparticles may lead to weak binding, 
which can accumulate on target cells. In other words, they 
supply detection with low sensitivity and specificity. For-
tunately, SPIONs can be simply bound to different types 
of molecules such as antibody, peptide, and aptamer with-
out compromising their affinity, targeting specific cancer 
biomarkers on the tumor cells (7). This plan would en-
hance the selective accumulation on target cells, which 
express high amounts of correlated biomarkers or recep-
tors on their surfaces. Subsequently, the desired effect can 
be augmented without leaking to adjacent healthy tissues. 
Antibodies are one of the most used biomolecules to meet 
the aim owing to their innate high specificity and large 
variety. Lots of tumor-associated antigens have been 
found as ideal candidates that can be targeted by antibod-
ies (8). 
Prostate stem cell antigen (PSCA) is a cell membrane 
marker that has been discovered to be overexpressed spe-
cifically in prostate cancer; however, its expression is lim-
ited in normal tissues (6, 9). The presence of this antigen 
is strongly associated with Gleason score, and it is up-
regulated in metastatic castration-resistant prostate cancer 
(mCRPC) lacking medication options (7, 10). Conse-
quently, PSCA can be considered a significant prognostic 
marker in prostate cancer imaging (1, 11), and evaluation 
of its expression on biopsies or blood screen can provide 
valuable information for clinicians regarding the aggres-
siveness and/or susceptibility to the metastatic behavior of 
established tumors (5, 12, 13). Consequently, the antibody 
against PSCA can be an appropriate option to be applied 
in actively targeting cancerous prostate cells by means of 
conjugation to nanoparticles.  
Conjugation of antibody to nanoparticles such as SPI-
ONs is a classical approach to target the cancer bi-
omarkers on the cell surfaces through specific antibody-
antigen interaction. Studies have shown that antibody-
conjugated nanoparticles have been used promisingly for a 
variety of biotechnological and biomedical manipulations 
(7, 14). Although many advances have been achieved in 
the conjugation, the purposeful bioconjugation of nano-
particles, which sustains the biological function and anti-
gen binding site of the antibody successfully in the appli-
cation of the antibody-conjugated nanoparticles, is still a 
challenge (14). To have a successful targeting, the conju-
gation method for each nanoparticle and antibody is re-
quired to be optimized.  Several oriented conjugation 
methods have been presented, one of which is covalent 
binding via carbohydrate moieties on the FC region of an 
antibody (15). In the current study, we conjugated dex-
SPIONs to the newly prepared anti-PSCA antibody 
against recombinant PSCA (rPSCA) protein by two dif-
ferent methods, including oxidizing carbohydrate moieties 
of FC regions and targeting the amine group of amino acid 
side chains of anti-PSCA antibody using sulfo-NHS. Iron 
staining was carried out to assess and compare the intensi-
ty of staining by anti-PSCA antibody-dexSPIONs by these 
methods in PC3 cells. Moreover, we compared the stain-
ing pattern of conjugated dexSPIONs with 20 and 100 nm 





A cell line of human prostate cancer, PC3, was obtained 
from the Pasteur Institute of Iran. The cell line was seeded 
in a medium called Roswell Park Memorial Institute 
(RPMI) (GIBCO, Rockville, MD), associated with 10% 
fetal bovine serum (FBS) (GIBCO) and 100 μg/ml strep-
tomycin /penicillin (GIBCO). The cells were cultured in a 
95% air humidified and 5% CO2 incubator for 10 days at 
37 ◦C.  
 
Preparation of rPSCA protein and anti-PSCA polyclonal 
antibody 
In the first phase of this experimental in vitro study, 
rPSCA protein and anti-PSCA polyclonal antibody were 
produced and purified for the next phase of conjugation 
assay. Expression vector for the human full PSCA (1-123 
aa) 6×-histidine (His) was constructed by subcloning the 
PSCA sequences into the pET28a vector between NdeI 
and XhoI enzyme restriction sites (GenScript Co., Ltd, 
USA, Inc). For affinity purification of rPSCA, the de-
signed vector had a C-terminal 6×-His tag before the stop 
codon. Escherichia coli (E.coli) BL21 strain (DE3, Pas-
teur Institute, Iran) was applied for rPSCA expression. 
Transformation and expression in competent cells of E. 
coli BL21 were done as previously described (16). Final-
ly, purification of the His-tagged PSCA protein was per-
formed by a Ni-NTA column (Invitrogen, CA, USA) 
based on the manufacturer's instructions and tested for 
purity and immunoreactivity using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) followed 
by staining with Coomassie blue (data not shown) and 
immunoblotting, respectively (17). 
Two rabbits were bought from the Pasteur Institute of 
Iran and injected with the purified rPSCA as emulsion 
associated with complete Freund’s adjuvant (first injec-
tion) and/or incomplete adjuvant (next injections). This 
vaccine was subcutaneously injected in several parts on 
the back of the rabbits. The first injection was performed 
with 300 μg of rPSCA associated with Freund’s complete 
adjuvant. In subsequent doses, a concentration of 150 μg 
of rPSCA was injected at three different times with two 
weeks interval. Each injection was combined with equal 
volumes of complete adjuvant and/or incomplete adjuvant. 
The blood was collected from the central artery of the 
rabbits’ ear before immunization and 10 days after each 
injection. ELISA was run to detect titrations of specific 
antibodies in the antisera based on a method previously 
determined by the corresponding author (18). 
 
Detection of rabbit antibody against rPSCA by ELISA 
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sayed via ELISA. Briefly, flat wells of ELISA plates 
(Nunc, Rochester, NY, USA) were coated with 3 µg/ml of 
rPSCA in 100 mM carbonate bicarbonate buffer (pH 7.2) 
and put at 4◦C for 24 hours (h), the wells were then 
blocked. One hundred μl of immunized rabbit serum was 
serially diluted, poured into the wells and put at 37°C for 
1 h. Goat anti-rabbit IgG as secondary antibody conjugat-
ed to horseradish peroxidase (HRP) (Santa Cruz Biotech-
nology, CA, USA) was then added in a 1:2000 dilution 
into the wells and incubated at 37°C for 1 h, and the wells 
were washed afterward (19). Tetramethyl benzidine liquid 
substrate (TMB, Roche) as a chromogenic substance was 
added to the wells, and color progression was stopped by 
0.2 M sulfuric acid. The data were picked up at the optical 
density (OD) of 450 nm by an ELISA reader (model 680, 
Bio-Rad, CA, USA). 
For purification of anti-PSCA antibody from anti-rabbit 
sera, the rPSCA was chemically bound to the beads of 
NHS-activated agarose (Pierce Chemicals Co., IL, USA) 
and purified according to the manufacturer’s methods 
(20). The amount of the purified anti-PSCA antibodies 
was assayed by BCA kit (Thermo Fisher Scientific, IL, 
USA) using the BSA (Bovine Serum Albumin) standard 
curve. 
 
Protein extraction & western blotting analysis 
Cultured PC3 cells were trypsinized and dissolved in 1 
M lysis buffer (2.4 gr urea, 5.1 gr thiourea, 4 gr CHAPS, 4 
ml of Tris buffer in 10 ml deionized water) and protease 
inhibitor cocktail (Sigma, MO, USA). Protein concentra-
tion in the supernatant was assayed by the BCA kit. Cell 
lysates and/or rPSCA protein (50 μg) were blended and 
boiled by loading buffer for 5 min and loaded onto 7% 
SDS–PAGE plus 10% SDS and β-mercaptoethanol. The 
proteins were transferred onto the polyvinylidene difluo-
ride (PVDF) membrane (240 mA for 45 min at 4°C) in 
transfer buffer of a wet western blot apparatus; the mem-
brane was then blocked for 1.5 h at RT (21). Afterward, 
1:1000 dilution of anti-PSCA antibody (0.8 mg/ml) was 
added to the membrane in TBS, incubated overnight at 
4°C and washed six times with TBS-T buffer. The goat 
anti-rabbit HRP-conjugated antibody (1:60000, Abcam, 
MA, USA) was then added for 1 h at RT. Finally, bands 
were exposed by enhanced chemiluminescence (ECL) 
(Pierce) and presented on an x-ray film (Roche). 
 
Immunocytochemistry 
The PC3 cells grew in 24-well plates at 37°C/5% CO2 
for 24 h. The cells were then washed with 100 mM PBS-T 
(pH 7.2), fixed in 4% paraformaldehyde (V/V) for 20 min, 
and blocked with 5% BSA in PBS-T for 45 min at RT. 
Subsequently, the cells were treated with anti-PSCA anti-
body as primary antibody diluted 1:1000 for 1 h at RT. 
The goat anti-rabbit IgG conjugated to FITC (Sigma) was 
added with a 1:160 dilution for 1 h at RT, and subsequent-
ly the nuclei of cells were stained with Hoechst solution 
(Thermo Fisher) and analyzed using an inverted fluores-
cence microscope (Olympus, Japan). The plates were 
washed with PBS-T (pH 7.2) between each step. PBS and 
equal concentration of IgG fraction from pre-immunized 
rabbit serum were applied as negative controls instead of 
the primary antibody (22). 
 
Oriented conjugation of purified polyclonal anti-PSCA 
antibody to SPIONs 
Preparation of Hydrazide-Activated SPIONs: SPIONs 
with a cross-linked dextran coating (dexSPIONs) contain-
ing-COOH group (nanomag®-CLD-spio 100 nm, Micro-
mod Partikeltechnologie GmbH, Rostock, Germany) and 
20 nm dexSPIONs, a gift from Nanochem Dept, Tehran 
University, were functionalized by adipic acid dihydrazide 
(Sigma Aldrich, USA). Briefly, 8 mg of adipic acid dihy-
drazide was dissolved in 250 µl of sodium phosphate (0.1 
M; pH 6.0), and then 2.5 mg of each dexSPIONs were 
dissolved in the prepared adipic acid dihydrazide solution. 
Eight mg of water-soluble carbodiimide 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) (Thermo 
Fisher, USA) were added and blended to them to dissolve 
completely (Fig. 1). The reaction was incubated for 4 h at 
RT. Finally, to remove the excess reagent and reaction by-
product, the solution was dialyzed against PBS (0.15 M; 
pH 7.2) overnight at 4°C (23). 
Activation of antibodies with sodium periodate: An ap-
propriate amount of anti-PSCA polyclonal antibody was 
dissolved in sodium phosphate (0.01 M; pH 7.2) and 0.15 
M NaCl. The carbohydrate moieties of anti-PSCA anti-
body (1 mg/ml) were oxidized by 20 µl of sodium perio-
date solution (0.1 M) (Fig. 1). The reaction was done in a 
dark room for 20 min and quenched by addition of sodium 
sulfite (Na2SO3). Ultimately, the oxidized antibody was 
purified using gel filtration via a desalting resin (G-50). 
One ml fractions were collected, and the protein content 
of the fractions was measured using a NanoDrop spectro-
photometry (Thermo Onec, USA) at 280 nm of light ab-
sorbance (23). 
After oxidizing the antibody by sodium periodate, con-
jugation was done by addition of 1 ml of desalted oxidized 
anti-PSCA antibody (100 µg/ml) and 500 µl of Hydra-
zide-Activated SPIONs (5 mg/ml) mixed and put at RT 
for 2 h, followed by blocking the unreacted aldehyde sites 
of the antibody through addition of 1 M ethanolamine, pH 
9.6. The compound was incubated at RT for 30 min. The 
unconjugated anti-PSCA antibody was removed using the 
MACS magnetic column (Miltenyi Biotec, Germany) (24) 
to obtain the resulting conjugated anti-PSCA antibody-
functionalized iron oxide nanoparticles (Fig. 1A). 
Conjugation of anti-PSCA antibody via amine groups of 
amino acid: In another experiment, 1 mg/ml of dexSPI-
ONs containing -COOH groups was activated by 0.05 M 
of 2-(N-morpholino) ethanesulfonic acid (MES) and 0.5 
M NaCl (pH 6.0). The activated nanoparticles were added 
to 2 mM EDC and 5 mM sulfo-NHS (Thermo Fisher) for 
15 min at RT to constitute the sulfo-NHS esters. The acti-
vated nanoparticles were purified from the reaction by gel 
filtration using a desalting resin. To conjugate, the activat-
ed nanoparticles were added to the anti-PSCA antibody 
dissolved in sodium phosphate (0.1 M; pH 7.5) for 2 h at 
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using the MACS magnetic column to get rid of un-reacted 
free antibodies (Fig. 1 B) (23). 
Cell staining by Perlʹs Prussian blue: The PC3 cells 
were seeded in 12-well plates and incubated for 24 h at 
37°C/ 5% CO2. They were washed with PBS-T, fixed for 
20 min in 4% paraformaldehyde (V/V), and incubated 
with 5% BSA/PBS-T for 45 min at RT. Subsequently, 
PC3 cells were incubated with anti-PSCA antibody conju-
gated dexSPIONs (70 µg/ml) and/or free dexSPIONs (as a 
control) for 2 h at RT. The dexSPIONs that mostly at-
tached to the cell surface were stained using Prussian Blue 
Iron Stain Kit (Polysciences, USA), and to stain the nu-
cleus; Nuclear Fast Red solution (Polysciences) was used. 
The plates were washed with PBS-T between each step. 
The PC3 cells were investigated under a light microscope 
(Olympus IX51; Olympus, Tokyo, Japan) at 10X and 40× 
magnifications. The AGS cell line (human epithelial 
stomach) was applied as a negative control cell (25, 26). 
 
Results  
Evaluation of anti-rPSCA anti-serum 
It has been established that rPSCA protein is immuno-
genic because the production of the anti-rPSCA antibody 
is strongly induced in the rabbit. The anti-sera showed 
reactivity with rPSCA by ELISA; whereas, IgG fraction of 
the rabbit pre-immune serum did not have any reactivity. 
ELISA results showed that antibody titers were convinc-
ingly high at >1/6400 dilution (Fig. 2 A). The specific 
antibodies purified by affinity chromatography were tit-
tered and determined at 1:12800 dilutions. The IgG frac-
tion of pre-immunized rabbit at the same dilutions was 
applied as a negative control (Fig. 2 B).  
 
Immuno-reactivity of anti-PSCA antibody by western 
blotting analysis 
To evaluate the specificity of anti-sera, Western blot 
analysis was done on PC3 and rPSCA to assay the expres-
sion of PSCA by anti-PSCA antibody. The cell lysates and 
rPSCA were analyzed on a PVDF membrane, as shown in 
Fig. 2 C. Specific bands approximately 26 (Fig. 2 C1) and 
15 kDa (Fig. 2 C2) were detected by anti-PSCA antibody 
in PC3 cells and rPSCA, respectively. The rPSCA pro-
duced in prokaryotic system migrates at a lower molecular 
weight than the cell line lysates, perhaps reflecting the 
absence of the covalent glycosylphosphatidylinositol 
(GPI)-linkage. The PSCA expression was almost high and 
moderate in PC3 and E. coli BL21 cells, respectively (Fig. 
2 C), while no band was found for non-immunized serum 
(data not shown). These results indicated that the pro-
duced anti-PSCA antibody could effectively recognize 
both human exogenous rPSCA and endogenous PSCA. 
 
Immunocytochemical analysis of PC3 cells using anti-
PSCA antibody 
We analyzed the staining pattern of PSCA in prostate 
cancer cells treated with anti-PSCA antibody by immuno-
cytochemistry. Immunocytochemical analysis of PC3 cell 
 
Fig. 1. Scheme of bioconjugation for anti-PSCA antibody-dexSPIONs. (A) DexSPIONs were functionalized by adipic acid dihydrazide via EDC. 
Carbohydrate positions of antibody were oxidized using sodium periodate (not shown) and linked toward activated dexSPIONs. (B) DexSPIONs 
were activated by MES (not shown), bound to EDC and sulfo-NHS and formed the sulfo-NHS esters. DexSPIONs containing sulfo-NHS esters 
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line by anti-PSCA antibody showed green fluorescence 
signals mostly on the cell surface stained with only FITC 
and merged images stained with FITC and Hoechst dyes. 
When these cells were treated with pre-immunized rabbit 
serum at an equal concentration with anti-PSCA antibody, 
ghost cells with weak fluorescence signal were observed 
(Fig. 3). 
 
Perlʹs Prussian blue staining of PC3 using anti-PSCA 
antibody-dexSPIONs 
To characterize the specific binding of anti-PSCA anti-
body-dexSPIONs and to evaluate the successful conjuga-
tion toward PSCA-expressing tumor cells, iron staining 
was performed on PC3 cells using Perlʹs Prussian blue 
staining. The pattern (iron and nuclear fast red staining) 




Fig. 2. Titration of anti-PSCA antisera by indirect ELISA (A) and the purified antibody against rPSCA (B). Western blot analysis of cell lysates 
(lane C1) and rPSCA (lane C2) detected using affinity purified anti-PSCA antibody (details have been described in the text).  
 
 
Fig. 3. Images of PC3 cell lines taken by immunofluorescence microscopy when treated with anti-PSCA antibody. A and C; PC3 cell lines incubat-
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containing substances. In this study, targeted conjugation 
via oxidizing carbohydrates of antibody FC by sodium 
periodate and treatment of the PC3 cells with conjugated 
nanoparticles were performed. A strong blue dye appeared 
by iron staining and showed a high accumulation of con-
jugated nanoparticles on the membrane of PC3 cells by 
oriented conjugation via oxidizing carbohydrates of anti-
PSCA antibody in comparison with cells that were not 
treated with anti-PSCA antibody-dexSPIONs (Fig. 4 A, 
C). Cells treated with non-conjugated dexSPIONs (Fig. 4 
C) and/or AGS cells (negative control; Fig. 4 D) treated 
with anti-PSCA antibody-dexSPIONs showed no blue 
stain, but their nuclei were stained. The results indicated 
that dex-SPIONs conjugated to anti-PSCA antibody via 
carbohydrate moieties of antibody FC strongly bound to 
PSCA in PC3 cells. However, when the amine groups of 
anti-PSCA antibody were targeted and conjugated to the 
activated dexSPIONs through sulfo-NHS, very weak sig-
nal in cells was observed in comparison with conjugation 
done by oxidizing carbohydrates of antibody (Fig. 4 A, 
B). The results indicated that targeted amine groups of 
antibody might affect the F(ab')2 amino acids responsible 
for antigen binding.  
Moreover, we compared the staining pattern of conju-
gated dexSPIONs with 20 and 100 nm diameters by oxi-
dizing the carbohydrates of anti-PSCA antibody. PC3 
cells treated with dexSPIONs at 20 nm diameter showed 
higher resolutions of blue color absorbance, and staining 
pattern was more specific than those treated with 100 nm 
nanoparticles (Fig. 4 E, F). These findings showed that the 
small size of SPIONs could enhance permeability as well 
as retention effect and might lead to accumulation of the 
particles in target tumor cells. 
 
Discussion 
Nanoparticles have attracted intensive research efforts 
due to their unique properties and low side effects in pa-
tients with cancer therapy, and are also used for the treat-
ment of other diseases. Among various types of nanoparti-
cles, SPIONs have attracted great attention for targeting 
tumor antigens in cancer therapy and imaging applications 
(24, 27, 28). Furthermore, targeting cell-surface antigens 
is critical for developing the diagnostic and therapeutic 
algorithm for the management of prostate cancer. Among 
all prostatic cancer cell-surface antigens, we selected 
PSCA as a favorite target for in vitro imaging of prostate 
cancer cells for its overexpression on the prostate cancer-
ous cell membrane (29). Moreover, PSCA is strongly ex-
pressed in both androgen-sensitive and in-sensitive pros-
tate tumors as well as prostate cancer patients with high 
Gleason grades (Gleason grades: 4 and 5). In the present 
study, we produced recombinant full-length PSCA in the 
competent cells of E. coli BL21 followed by production of 
rabbit antibody against the protein. The analysis of ELISA 
results showed that rPSCA was immunogenic in rabbit 
such that the antibody produced against the rPSCA was at 
high titers. Our Western blot analysis represented a specif-
ic band at 26 kDa when the antibody was used, indicating 
that the rabbit antibody produced by rPSCA can specifi-
cally react to the PSCA protein found in prostate cancer 
cells. 
Herein, we conjugated anti-PSCA antibody to a dex-
SPIONs, as illustrated in Fig. 1. To activate dexSPIONs, 
we used two different chemical agents, including adipic 
 
Fig. 4. I, PC3 cells stained with iron, after treatment with anti-PSCA antibody conjugated to dexSPIONs. A: Oriented conjugation of dexSPIONs 
to anti-PSCA antibody through carbohydrate moieties of antibody FC by adipic acid dihydrazide. B: Conjugation of anti-PSCA antibody via amine 
groups of amino acids by sulfo-NHS. C: PC3 cells were treated with non-conjugated dexSPIONs (negative control). D: AGS cells (negative con-
trol) treated with anti-PSCA antibody-dexSPIONs (details have been described in the text). II, Comparison of iron staining pattern between 
dexSPIONs with 20 nm and 100 nm diameters. E: dexSPIONs with 20 nm diameters conjugated to anti-PSCA antibody, F: dexSPIONs with 100 
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acid dihydrazide and sulfo-NHS to alter the surface of the 
dextran-coated SPIONs. This process produced the acti-
vated dexSPIONs with hydrazide and/or sulfo-NHS ester 
groups for the subsequent antibody conjugation step. With 
two different methods, carbohydrate moieties in the oligo-
saccharide groups and amines of amino acid side chains of 
anti-PSCA antibody were targeted and then conjugated to 
the hydrazide and/or sulfo-NHS ester groups on the sur-
face of the dexSPIONs to provide the antibody-
functionalized dexSPIONs (anti-PSCA antibody-
dexSPIONs). Although there are a wide variety of oxida-
tive reactions for aldehyde group formation of antibody 
carbohydrates, sodium periodate was the more favorable 
option due to lack of adverse reactions, forming aldehyde 
groups on the carbohydrate moieties of antibodies without 
changing the solubility of the antibody (14). When nano-
particles were conjugated through carbohydrate moieties 
of the FC domain, stronger signals were observed in com-
parison with a reaction in which it conjugated through 
amine side chains of the antibody. Gao et al. at 2012 tar-
geted free sulfhydryl groups on scAb by using maleimide-
polyethylene glycol-COOH linker to conjugate the SPI-
ONs to single chain antibody against PSCA, (12). Given 
that the sulfhydryl groups may form in Fab area of anti-
body due to the presence of the cysteine group, this meth-
od may be involved in blocking the binding site of the 
antibody to the antigen. Shamsipour et al. conjugated anti-
her2/neu monoclonal antibody (Herceptin) to SPIO nano-
particles via amine groups of amino acid antibody using 
EDC method (30). The limitations of nanoparticle conju-
gation to an amine group of the antibody are due to the 
residues of the amino acids (such as lysine) in an antibody 
that accidentally bind to nanoparticle linkers, and the anti-
gen-binding sites of antibody (F(ab') 2) would not be pre-
sented towards tumor cell antigens. These specs may re-
sult in lower binding capacity and therefore affect the 
therapeutic and/or diagnostic application of the bioconju-
gation. Our results indicated that directed conjugation 
through carbohydrate moieties of the CH2 domains of 
antibodies could result in highly efficient detection of the 
prostate cancer cells by PSCA protein. Consequently, the 
method presented in this study can be successfully applied 
to the antibody modification reaction beyond the antigen-
binding sites for the diagnosis of prostate cancer cells.  
Furthermore, by decreasing the size of iron oxide parti-
cles into nanometer ranges, iron ions perform a major role 
on the surface of nanoparticles to do more efficient bio-
conjugation (31). Consequently, to increase the imaging 
sharpness and tumor detection accuracy with nanoparti-
cles, it is essential to note the physical features of nano-
particles, including size and surface/volume ratio. It has 
been revealed that these properties of nanoparticles play a 
pivotal role in effective transport into tumor microcircula-
tion (32). In general, renal clearance can clear the nano-
particles that are smaller than 5–10 nm from circulation , 
and by increasing the size of nanoparticles, they primary 
accumulate in the spleen and liver (33). To explore the 
efficacy of SPIONs with different sizes in imaging of 
prostate cancer cells, we compared the staining patterns of 
two different dexSPIONs with 20 and 100 nm in diameter 
by oxidizing the carbohydrate moieties of the antibody. 
Our findings showed that SPIONs with 20 nm diameter 
obtain a higher resolution in comparison with 100 nm- 
diameter nanoparticles. The results indicated that the 
small size of SPIONs is also determinative for the reten-
tion effect on the tumor cells and increased permeability, 
which in turn leads to concentration of the nanoparticles 
on target cells. Therefore, controlling the nanoparticle size 
toward the favorable range can be effective in delivery 
vehicles that deal with tumor cells. 
 
Conclusion  
In the present study, we targeted PSCA antigen on the 
PC3 cells by preparing anti-PSCA antibody conjugated to 
nanoparticles. The results showed strongly stained cells 
expressing PSCA by orientated conjugation of the anti-
body via carbohydrate groups of antibody FC region, sug-
gesting a possible new approach for better cancer imaging 
and targeting strategies. Moreover, the findings showed 
that considering SPION size within the desirable range 
can result in better staining of tumor cells and may affect 
the penetration capacity of nanoparticles in tumor cells. 
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